Clinical Trial Update: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) [Phase 2, Phase 3]

View source ↗

Summary

APEX-03 is a Phase 2/3 clinical trial evaluating ICP-248 in combination with orelabrutinib for treatment-naïve chronic lymphocytic leukemia and small lymphocyti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• ICP-248
• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Hematologic Malignancies | Phase 2, Phase 3 | Status: RECRUITING